Project Grant R37CA285794
Award Date
7/1/24
Completion Date
6/30/29
Dollars Obligated
$661K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $626,893 to The University of Texas MD Anderson Cancer Center to advance the understanding of how bacterial communities within tumors interact with and influence the tumor microenvironment. The key objectives are to: Functionally map the spatial distribution and cellular/metabolic features of bacterial-colonized microniches within patient tumor tissues. Identify human cell types...
The federal Project Grant award R01CA285882, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research to identify intratumoral microbiome profiles and spatial immune signatures that can predict response to immune checkpoint inhibitor (ICI) therapy in non-small cell lung cancer patients. The $684,367 award to Baylor College of Medicine will leverage existing tumor sample repositories and clinical data from three independent patient...
This $295,881 Project Grant awarded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to advance a novel antimicrobial approach to treat chemoradiation-resistant cervical cancer. The grant recipient, Osel, Inc., will synthesize and characterize the bacteriocin GASK7B, which selectively inhibits the pathogenic Lactobacillus iners strain associated with decreased survival in cervical cancer patients undergoing treatment. The project will evaluate GASK7B's in vitro...
This federal Project Grant award of $697,763.00 from the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) program supports research by the University of Texas MD Anderson Cancer Center to investigate the genetic factors that enable the Fusobacterium nucleatum (Fn) bacterium to colonize and persist within colorectal cancer (CRC) tumors. The study aims to provide mechanistic insights into how the Fn CRC-specific clade pathoadapts to the tumor microenvironment,...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research to investigate the role of bacterial DNA methyltransferases in colorectal cancer development and progression. The $1,384,482 award to the University of Texas MD Anderson Cancer Center aims to determine if a specific DNA methyltransferase enzyme from the bacterium Fusobacterium nucleatum contributes to its pathoadaptation in the tumor microenvironment and impacts the human host...
This $654,763 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to define the mechanistic basis of how the gut microbiome produces androgen metabolites that can promote resistance to androgen-targeted therapies and inhibit anti-tumor immunity in metastatic castration resistant prostate cancer. The lead grantee, The Johns Hopkins University, will conduct studies to determine if microbial-derived androgens are sufficient to...
This $112,230 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The grant is being used by the University of Texas MD Anderson Cancer Center to conduct research on the role of gut microbiome dysbiosis in the development and progression of lung adenocarcinoma (LUAD), the most common type of non-small cell lung cancer. The research aims to determine how gut dysbiosis impacts immunomodulation and inflammation...
This Project Grant award, provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) federal grant program, aims to improve bacterial cancer therapeutics. The $253,405 award to The Trustees of Columbia University in the City of New York, awarded on Aug 23, 2024, will support research to identify mechanisms by which bacteria, particularly Escherichia coli, can selectively migrate to and grow within tumors. This information will be leveraged to develop bacterial...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program provides $426,425 to Baylor College of Medicine to conduct a pilot study examining the relationship between gut microbiome composition, metabolic dysfunction-associated steatotic liver disease (MASLD), and hepatocellular carcinoma (HCC). The key objectives are to: 1) characterize gut microbiome diversity in MASLD patients with and without HCC, 2) correlate...
This National Cancer Institute (NCI) Project Grant award under the Cancer Research Manpower (CFDA 93.398) program provides $112,026.00 to The University of Texas MD Anderson Cancer Center to investigate the role of the oral microbiota in the development and progression of brain metastases. The funded research aims to elucidate the mechanisms by which the oral microbiome influences the formation of the tumor microbiome in brain metastases, and to determine the local and systemic contribution of...